Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romilkimab - Sanofi

Next Previous
Drug Profile

Romilkimab - Sanofi

Alternative Names: Bispecific IL4/IL13 antibody - sanofi-aventis; IL4/IL13 bi-specific monoclonal antibody - sanofi-aventis; SAR 156597; SUB33159

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antifibrotics; Bispecific antibodies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis; Systemic scleroderma

Most Recent Events

  • 08 Nov 2019 Efficacy and adverse events data from a phase II trial in Systemic scleroderma presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
  • 07 Feb 2019 Sanofi announces intention to submit regulatory application for Systemic Scleroderma in 2023
  • 18 May 2018 Efficacy and safety data from a phase II trial in Idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top